奥妥珠单抗治疗难治性肌炎的 реаль世界病例系列
该病例系列纳入5例符合2017 EULAR/ACR分类标准的特发性炎症性肌病患者,因利妥昔单抗过敏或尽管使用利妥昔单抗仍出现ILD和肌炎活动加重、关节炎或严重皮疹而接受奥妥珠单抗治疗;80%患者在3-6个月内总体改善,所有ILD患者呼吸状态改善或稳定,末次观察时4/5达到完全缓解,未观察到低丙种球蛋白血症、显著感染或住院。
要点
- 奥妥珠单抗在利妥昔单抗过敏的难治性肌炎患者中安全且提供持久改善
- 80%患者在3-6个月内总体改善,所有ILD患者呼吸状态改善或稳定
- 末次观察时4/5患者达到完全缓解,未观察到低丙种球蛋白血症或显著感染
核心结论
- 奥妥珠单抗在利妥昔单抗过敏的难治性肌炎患者中安全且提供持久改善,进一步突显靶向B细胞通路的价值。
研究设计与样本
- 收集人口学、临床、血清学和影像学数据,基于临床反应和医师整体评估将总体反应评定为完全、部分或无反应;因数据回顾性收集未计算总改善评分,采用描述性统计。
主要发现
- 5例患者中2例为抗合成酶综合征、1例皮肌炎、2例重叠肌炎,多数患者至少对3种免疫抑制剂治疗失败。
- 使用奥妥珠单抗的原因包括利妥昔单抗过敏以及尽管使用利妥昔单抗仍出现ILD和肌炎活动加重(3/5)、关节炎(2/5)和严重皮疹(1/5)。
- 奥妥珠单抗治疗后80%患者在3-6个月内总体改善,所有ILD患者呼吸状态改善或稳定。
- 2例患者需第二周期奥妥珠单抗(1例因复发、1例因疾病持续伴B细胞再填充),其中1例第二周期后失访并判定为无反应者。
- 末次观察时4/5患者达到完全缓解,未观察到低丙种球蛋白血症、显著感染或住院。
关键数值与推荐
- 5例患者均符合2017 EULAR/ACR IIM分类标准。
- 总体反应基于临床反应和医师整体评估评定为完全、部分或无反应。
- 80%患者在3-6个月内总体改善,末次观察时4/5达到完全缓解。
临床怎么用
- 对于利妥昔单抗过敏或尽管使用利妥昔单抗仍出现ILD和肌炎活动加重、关节炎或严重皮疹的难治性IIM患者,可考虑奥妥珠单抗作为B细胞靶向治疗选择。
- 治疗期间需监测B细胞再填充和疾病复发,部分患者可能需要第二周期奥妥珠单抗。
局限性
- 回顾性病例系列,样本量仅5例,未计算总改善评分,描述性统计分析。
- 1例患者第二周期后失访并判定为无反应者,可能影响结局评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Idiopathic inflammatory myopathy (IIM) is an orphan systemic disorder with muscular, cutaneous and pulmonary involvement. B cell-directed therapies, including rituximab, belimumab and chimeric antigen receptor T-cell (CAR-T), have shown promise in altering disease outcome. We report the benefit of obinutuzumab in difficult -to- treat myositis patients. METHODS: The Northwell Rheumatology database was searched for obinutuzumab-treated patients (2019-24); five of them met 2017 EULAR/ACR classification criteria for IIM and were included in the analysis. Demographic, clinical, serological and imaging data were collected. Overall response was rated as complete, partial or no response based on clinical response and physician global assessment. Total improvement score was not calculated because data were collected retrospectively. Descriptive statistics were used for analyses. RESULTS: Of five patients, two had antisynthetase syndrome, one dermatomyositis (DM) and two overlap myositis. Most patients failed at least three immunosuppressive agents. The reason for obinutuzumab use was rituximab allergy and worsening of interstitial lung disease (ILD) and myositis activity (3/5), arthritis (2/5) and severe rash (1/5 patients), despite rituximab. After obinutuzumab 80% of patients had overall improvement by 3-6 months. Respiratory status improved/stabilized in all ILD patients. Two patients required second obinutuzumab cycle: one for recurrence and another for persistent disease with B cell re-population. One was lost to follow-up after the second cycle and was deemed a non-responder. At last observation, 4/5 patients had achieved a complete response. No hypogammaglobulinaemia, significant infections or hospitalizations were observed. CONCLUSION: Obinutuzumab was safe and provided durable improvement in difficult-to-treat myositis patients with rituximab allergy, further highlighting targeting the B-cell pathway.
引用
- Ilic I, Narain S, Marder G, et al. Real-world experience with obinutuzumab in difficult-to-treat myositis: concise report of a case series. Rheumatology (Oxford). 2026. PMID: 42640578. doi:10.1093/rheumatology/keag435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。